Sagimet Biosciences Inc. - Series A · NASDAQ:SGMT
Sagimet Biosciences Inc. - Series A — Sagimet Biosciences — Investor Presentation (April 2026)
22 slides from Sagimet Biosciences Inc. - Series A's investor presentation, Apr 27, 2026
Slide 1: Targeting Metabolic Dysfunction with Novel Therapeutics
Targeting MetabolicDysfunction with Novel Therapeutics April 2026
Slide 2: Forward-Looking Statements and Disclaimer
April 2026 2 Forward-Looking Statements and Disclaimer This presentation contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this document, other than statemen
Slide 3: Leadership Team with Proven Development and Commercialization Experience
April 2026 3 DaveHappel President&CEO >20 years of experience in executive leadership in biotech and pharma Brought multiple innovative healthcare products to the market Andreas Grauer Chief Medical Officer > 20 years of experience in Clinical Development and Medical Affairs across a broad range of
Slide 4: Sagimet at a Glance: Differentiated Dermatology Assets with Clinical Validation
April 2026 4 TVB-3567 in Acne Unique MOA: FASN Inhibition Sagimet at a Glance: Differentiated Dermatology Assets with Clinical Validation • Our lead molecule, denifanstat, is a novel fatty acid synthase (FASN) inhibitor with a differentiated method of action with the potential to target multiple und
Slide 5: Denifanstat in Other Indications; Strong IP, Cash Position, and Collaboration Potential
April 2026 5 Denifanstat in Other Indications Strong IP, Cash Position, and Collaboration Potential • Successful outcome of Phase 2b clinical trial in MASH (metabolic dysfunction-associated steatohepatitis); met both primary endpoints with significant reduction in fibrosis • Pre-clinical data demons
Slide 6: Development Pipeline: Multiple Indications and Clinical Milestones
April 2026 6 Therapeutic Area Indication Stage of Development Milestone / Program Updates Preclinical Phase 1 Phase 2 Phase 3 Dermatology Acne Phase 3 clinical trial for the US expected to initiate in 2H 2026 Phase 1 FIH clinical trial initiated in June 2025 Topical formulation in development Met al
Slide 7: FASN Inhibition Offers Differentiated MOA in Acne
FASN Inhibition Offers Differentiated MOA in Acne
Slide 8: Potential Role of FASN Inhibitors in the Pathogenesis of Acne
April 2026 8 4 key drivers of acne1: • Increased sebum in sebaceous glands (80% of lipids produced through DNL)2 • Abnormal or excessive follicular hyper-keratinization • Accelerated bacterial growth (C. acnes) • Localized inflammatory response Potential Role of FASN Inhibitors in the Pathogenesis o
Slide 9: Acne Market Overview
April 2026 9 Blackheads Whiteheads Papules & Pustules Cysts & Nodules Acne Market Overview Global acne market is expected to reach $20B by 20341 50 million people suffer with acne in the US annually2 • Acne is one of the most common skin conditions in the United States, with approximately 50 million
Slide 10: Acne Treatment Algorithm
April 2026 10 Mild Disease Moderate to Severe Disease Acne Treatment Algorithm Disease management involves flare and prevention intervention Treatment includes topical agents used as mono or combination therapy Main topical therapies: • Retinoids • Benzoyl Peroxide • Antibiotics • Clascoterone • Sal
Slide 11: Denifanstat's Clinical Data in Acne
Denifanstat’s Clinical Data in Acne
Slide 12: Pharmacodynamic Data Support Mechanism of Action of Denifanstat in Acne
April 2026 12 Pharmacodynamic Data Support Mechanism of Action of Denifanstat in Acne • Demonstrated a >90% reduction in sebum lipids by day 151,2 • Maintained the reduced level of sebum lipids through the entire study1,2 • Demonstrated a dose responsive impact on sebum lipids1,2 Note: denifanstat d
Slide 13: Ascletis Acne Phase 3 Clinical Trial Design
April 2026 13 Ascletis Acne Phase 3 Clinical Trial Design • Moderate to severe acne • Multi-center placebo controlled • 1:1 randomization • Double-blind • Once daily oral dosing • 480 patients in China Co-primary endpoints at week 12 • % patients who achieve IGA success (defined as at least a 2-poin
Slide 14: Ascletis Acne Phase 3 Clinical Trial Met All Primary and Secondary Endpoints
April 2026 14 Ascletis Acne Phase 3 Clinical Trial Met All Primary and Secondary Endpoints Baseline Characteristics 50mg denifanstat (n=240) Placebo (n=240) Total lesion count 102.2 102.1 Inflammatory lesion count 42.1 43.1 IGA=3 (moderate), % 85.8 85.8 IGA=4 (severe), % 14.2 14.2 Efficacy endpoints
Slide 15: Ascletis Acne Phase 3 Clinical Trial Safety Data
April 2026 15 Ascletis Acne Phase 3 Clinical Trial Safety Data* Denifanstat 50mg was generally well tolerated during the 12-week study Treatment-emergent adverse events (TEAEs): • TEAE incidence rates were comparable between denifanstat and placebo • Only two categories of TEAEs had an incidence rat
Slide 16: Ascletis Acne Open Label Phase 3 Trial
April 2026 16 Ascletis Acne Open Label Phase 3 Trial* Denifanstat generally well-tolerated in the open label clinical trial * Ascletis data on file. Safety and efficacy endpoints of 50 mg denifanstat oral, once daily for 52 weeks versus placebo for 12 weeks and 50mg denifanstat oral once daily for 4
Slide 17: Sagimet's Upcoming Development Programs
Sagimet’s Upcoming Development Programs
Slide 18: Phase 3 Clinical Trial Design for Denifanstat in Acne
April 2026 18 Phase 3 Clinical Trial Design for Denifanstat in Acne • Moderate to severe acne • Multi-center placebo controlled • 2:1 randomization • Double-blind • Once daily oral dosing • 800 patients in US Co-primary endpoints at week 12 • % patients who achieve IGA success (defined as at least a
Slide 19: FASN Inhibitor TVB-3567 FIH Ongoing Phase 1 Clinical Trial
April 2026 19 A double-blind, randomized, placebo-controlled clinical trial to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple ascending doses of TVB-3567 in healthy participants with or without acne • Includes sebum analysis as pharmacodynamic readout 1
Slide 20: Potential Clinical Development Program for TVB-3567 in Acne
April 2026 20 Potential Clinical Development Program for TVB-3567 in Acne Step 1 - Phase 1 first-in-human pharmacokinetic (PK) clinical trial of TVB-3567 in healthy volunteers • PK and pharmacodynamics (PD) evaluation to confirm profile • Assess safety/tolerability • Identify potential doses for an
Slide 21: Denifanstat for Treatment of MASH
April 2026 21 Denifanstat for Treatment of MASH Clinical and pre-clinical data demonstrate denifanstat’s potential to treat MASH (metabolic dysfunction-associated steatohepatitis) • MASH F2-F3: • Denifanstat met both primary endpoints in Phase 2b clinical trial, with significant reduction in fibrosi
Slide 22: FASN Inhibition – Significant Opportunity for a Novel Treatment for Acne
April 2026 22 FASN Inhibition – Significant Opportunity for a Novel Treatment for Acne FASN Inhibition in Acne Potential of TVB-3567 in Acne • Acne market is significant (~50m people in the US) and aligned to those patients most likely to be prescribed an oral FASN inhibitor • Oral FASN inhibitors o
Sagimet Biosciences — Investor Presentation (April 2026) on 6ix